Jerry Clark+FollowFlu & Covid Shots in One? Novavax Steps UpHeads up if you hate getting poked twice: Novavax just announced their combo flu and Covid shot looks promising in trials—think one-and-done for your fall vaccines. Meanwhile, Moderna hit pause on their own combo, so Novavax could have a head start. If you’re watching stocks, Novavax is up a smidge, but still down big this year. Could this new shot change the game for your next pharmacy run? #HealthNews #VaccineUpdate #Novavax #Business #Industry22Share
Allison Bauer+FollowNovavax’s Big FDA Win Sends Shares SoaringNovavax just got its COVID shot fully approved by the FDA, making it the only non-mRNA option in the US—and investors are loving it. The stock popped over 20%! This is a huge move, especially with vaccine access in the spotlight lately. Meanwhile, solar stocks are taking a hit as lawmakers threaten to cut clean energy tax credits, and China’s not happy about new US chip restrictions. Wild day in the markets! #Novavax #FDAApproval #StockMarket #CovidVaccine #SolarStocks #Health00Share
nheath+FollowNovavax’s COVID Vax: Not for Everyone?Novavax just got full FDA approval, but there’s a catch: it’s only for people 65+ or those 12-64 with health risks. Unlike Pfizer and Moderna’s mRNA shots, Novavax is protein-based (fewer side effects, anyone?). But with the FDA shaking up vaccine rules, next fall’s booster options might look way different. If you’re tired of shots, nasal vaccines could be on the horizon! #Novavax #COVID19 #VaccineUpdate #FDA #HealthNews #Health00Share
Adam Cox+FollowFDA’s New COVID Shot Rules—What’s Up?The FDA just gave Novavax’s new COVID shot the green light, but only for seniors and high-risk folks—not everyone. Unlike Pfizer and Moderna, which are approved for anyone 12+, Novavax’s shot is limited to those 65+ or people 12-64 with health risks. Plus, the FDA wants more safety data, especially for heart issues. And heads up: the whole vaccine approval process might be changing soon, with talks of new rules and even dropping COVID shots from the kids’ vaccine list. Stay tuned! #COVID19 #Novavax #FDA #VaccineUpdate #HealthNews #Health47Share
reyesbrian+FollowNovavax Finally Gets the Green LightNovavax just scored long-awaited FDA approval for its COVID-19 vaccine, and their stock shot up 15%! The catch? It’s only for folks 65+ or anyone 12+ with health risks. This is a big deal for people who wanted a non-mRNA option (think: not Pfizer or Moderna). Novavax is teaming up with Sanofi to roll it out this fall, but they’ll need more approvals for future updates. Big pharma drama, anyone? #Novavax #COVID19 #VaccineNews #FDA #HealthUpdates #Health00Share
Barry Miller+FollowNovavax’s Big FDA Win Sends Stock SoaringNovavax just got the green light from the FDA for its new protein-based COVID-19 shot, Nuvaxovid, and their stock shot up 25%! This vaccine is aimed at older adults and people with health conditions, and it’s different from the usual mRNA shots. Plus, Sanofi is teaming up with them and dropping $175 million on the deal, with more royalties on the way. Looks like Novavax is back in the game! #Novavax #COVID19 #VaccineNews #StockMarket #FDAApproval #Health01Share
nheath+FollowNew Covid Shot, But Only for SomeThe FDA just greenlit a new Covid vaccine from Novavax, but here’s the catch: it’s only for people 65+ or those 12-65 with health risks. Unlike the usual mRNA shots, this one’s protein-based—so if you’ve been holding out for something different, this might be your moment (if you qualify). People are already debating the restrictions and whether it should be more widely available. Would you try this new option if you could? #CovidVaccine #Novavax #FDA #HealthNews #VaccineUpdate #Health322Share
Stacy Fisher+FollowNovavax Vax Finally Gets FDA Green LightAfter weeks of waiting, Novavax’s Covid-19 vaccine just got FDA approval—but only for people 65+ or anyone 12+ with a health condition that puts them at higher risk. Unlike Pfizer and Moderna’s mRNA shots, Novavax uses a more old-school protein-based tech. The FDA wants more studies on rare heart inflammation risks, but experts say the benefits still outweigh the risks for those who need it most. Looks like there’s a new option for high-risk folks this season! #Novavax #Covid19Vaccine #FDAApproval #HealthNews #VaccineUpdate #Health21Share
Stephanie Snow+FollowNovavax Gets the Green Light—But With a CatchNovavax’s COVID-19 vaccine just scored full FDA approval, but here’s the twist: it’s only for people 65+ or those 12–64 with health risks. Unlike Pfizer and Moderna, this protein-based shot isn’t for everyone yet—kids under 12 are still waiting on more data. The FDA’s also asking for more studies, especially on heart safety. If you’ve been holding out for a non-mRNA option, this could be your moment (if you qualify)! #Novavax #COVID19Vaccine #FDAApproval #HealthNews #VaccineUpdate #Health10Share
elizabethwang+FollowNovavax Vax Gets Green Light—With a CatchThe FDA just approved Novavax’s COVID vaccine, but there’s a twist: it’s only for people 65+ or anyone 12-64 with a health condition that ups their COVID risk. No word yet on what counts as an ‘underlying condition’—classic FDA move. If you were hoping for a new vax option for kids, you’ll have to wait; those studies aren’t done yet. Big milestone for Novavax, but definitely not a free-for-all! #Novavax #COVID19 #FDAApproval #VaccineUpdate #Health20Share